ERBB2 and breast carcinoma: Biomarkers for CDK4/6 inhibitors have been thoroughly investigated through molecular profiling of tumor material, but to date, the only clinically available biomarker remains breast cancer subtype as defined by traditional tissue markers (i.e., ER+/HER2-)[21,22].